<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964584</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2019_1</org_study_id>
    <nct_id>NCT03964584</nct_id>
  </id_info>
  <brief_title>Evaluation of the Neurological and Psychiatric Adverse Events of Dolutegravir and Bictegravir in Real Life</brief_title>
  <acronym>NEPALE</acronym>
  <official_title>Evaluation of the Neurological and Psychiatric Adverse Events of Dolutegravir and Bictegravir in Real Life (NEPALE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The neurological and psychiatric adverse effects of antiretroviral drugs is a concern for
      clinicians and people living with HIV. In addition, clinical trials conducted prior to market
      authorization often have stric inclusion and exclusion criteria in terms of age, co-morbidity
      or co-medication, and the patients included in the studies are not always representative of
      the population for whom the drugs will be prescribed in real life. We propose a prospective
      cohort study to assess the occurrence of neurological and psychiatric adverse events in HIV+
      patients starting an association with dolutegravir or bictegravir.

      Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological
      and psychiatric disorders will be assessed using self-administered questionnaires, at
      inclusion, one month, three months and six months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Low scientific relevance due to the marketing of new treatments, and expected inclusion
    difficulties
  </why_stopped>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of at least one of the following neurological or psychiatric disorders</measure>
    <time_frame>6 months</time_frame>
    <description>depression, defined by a CES-D score ≥ 17 for men and ≥ 23 for women
anxiety, defined by a STAI score ≥ 56 (high anxiety); a score &gt; 65 indicating very high anxiety;
pathological fatigue, defined by a score on the EMIF-SEP scale ≥ 45/100;
presence of a neurological symptom identified by the QES questionnaire.</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV+ Patients</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>assessment of neurological and psychiatric disorders by self-administered questionnaires</intervention_name>
    <description>Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected patients who need to initiate or modify antiretroviral therapy, and starting a
        combination of antiretroviral agents including dolutegravir or bictegravir.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 18 years

          -  HIV-infected

          -  Initiation or modification of antiretroviral therapy, and starting a therapeutic
             combination including dolutegravir or bictegravir

        Exclusion criteria:

          -  Intolerance to dolutegravir or bictegravir

          -  Addiction to a psychoactive product (drugs or medications) with the exception of amyl
             nitriles (&quot;poppers&quot;) and occasional recreational cannabis

          -  Alcohol consumption &gt;10 standard drinks/week

          -  Active HCV coinfection

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dolutegravir</keyword>
  <keyword>dictegravir</keyword>
  <keyword>Neurological disorder</keyword>
  <keyword>Psychiatric disorder</keyword>
  <keyword>HIV integrase Inhibitors</keyword>
  <keyword>Adverse drug event</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

